Murat Muhtar YILMAZER, Taliha ÖNER, Selman GÖKALP, Önder DOKSÖZ, Barış GÜVEN, Özgür VUPA-ÇİLENGİROĞLU, TİMUR MEŞE, Vedide TAVLI

Risk factors for persistence of coronary artery abnormalities in Turkish children with Kawasaki disease

The aim of this study was to identify the risk factors for persistence of coronary artery abnormalities (CAAs) in Kawasaki disease and to compare the differences between complete (n=25) and incomplete (n=18) forms of the disease in relation to CAAs. The patients’ demographic (age and sex), clinical (season of admission, duration of fever, form of Kawasaki disease), laboratory (complete blood count, eosinophil count, serum biochemistry, C-reactive protein level, erythrocyte sedimentation rate [ESR], urinary analysis), echocardiographic and therapeutic data were evaluated retrospectively from the medical records. The incidence of sterile pyuria was nearly twofold greater in patients with initial CAAs than in patients in which CAAs were not present (25% and 13%, respectively; p=0.33). In multivariate logistic regression analysis, ESR and pyuria were found to be associated with persistence of CAAs (p=0.035 and p=0.046, respectively). In addition, we found that duration of fever was significantly associated with persistence of CAAs (p=0.045). However, gender, age at presentation, peripheral blood eosinophilia, low albumin level, CRP, leukocytosis and anemia were not predictive for persistence of CAAs. There was no difference between the complete and incomplete form of the disease in regard to persistence of CAAs. As a result, we have determined that duration of fever, high levels of ESR and presence of sterile pyuria can be used to predict the persistence of CAAs in Kawasaki disease.

PDF

___

1. Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974; 54: 271-276.

2. Kotani S. Evaluation of evidence related to streptococci in the etiology of Kawasaki disease. Prog Clin Biol Res 1987; 250: 101-111.

3. Hamashima Y, Kishi K, Tasaka K. Rickettsia-like bodies in infantile acute febrile mucocutaneous lymph-node syndrome. Lancet 1973; 2: 42.

4. Burns JC, Geha RS, Schneeberger EE, et al. Polymerase activity in lymphocyte culture supernatants from patients with Kawasaki disease. Nature 1986; 323: 814-816.

5. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004; 110: 2747-2771.

6. Kim T, Choi W, Woo CW, et al. Predictive risk factors for coronary artery abnormalities in Kawasaki disease. Eur J Pediatr 2007; 166: 421-425.

7. Honkanen VE, McCrindle BW, Laxer RM, Feldman BM, Schneider R, Silverman ED. Clinical relevance of the risk factors for coronary artery inflammation in Kawasaki disease. Pediatr Cardiol 2003; 24: 122-126.

8. Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991; 324: 1633-1639.

9. Kato H, Sugimura T, Akagi T, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 1996; 94: 1379-1385.

10. Xiu-Yu S, Jia-Yu H, Qiang H, Shu-Hui D. Platelet count and erythrocyte sedimentation rate are good predictors of Kawasaki disease: ROC analysis. J Clin Lab Anal 2010; 24: 385-388.

11. Nakamura Y, Yashiro M, Uehara R, et al. Use of laboratory data identify risk factors of giant coronary artery aneurysms due to Kawasaki disease. Pediatr Int 2004; 46: 33-38.

12. Oki I, Tanihara S, Ojima T, Nakamura Y, Yanagawa H. A multicenter collaborative study on the risk factors of cardiac sequelae due to Kawasaki disease: a one-year follow-up study. Acta Paediatr 2000; 89: 1435-1438.

13. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 1998; 17: 1144-1148.

14. Freeman AF, Shulman ST. Refractory Kawasaki disease. Pediatr Infect Dis J 2004; 23: 463-464.

15. Rowley AH. Incomplete (atypical) Kawasaki disease. Pediatr Infect Dis J 2002; 21: 563-565.

16. Research Committee on Kawasaki Disease. Report of Subcommittee on Standardization of Diagnostic Criteria and Reporting of Coronary Artery Lesions in Kawasaki Disease. Tokyo: Ministry of Health and Welfare; 1984.

17. Harada K, Yamaguchi H, Kato H, et al. Indication for intravenous gamma globulin treatment for Kawasaki disease. In: Takahashi M, Taubert K (eds). Proceedings of the Fourth International Symposium on Kawasaki Disease. Dallas, Tex: American Heart Association; 1993: 459-462.

18. Falcini F. Kawasaki disease. Curr Opin Rheumatol 2006; 18: 33-38.

19. Shulman ST, Rowley AH. Advances in Kawasaki disease. Eur J Pediatr 2004; 163: 285-291.

20. Anderson MS, Todd JK, Glodé MP. Delayed diagnosis of Kawasaki syndrome: an analysis of the problem. Pediatrics 2005; 115: 428-433.

21. McCrindle BW, Li JS, Minich LL, et al. Coronary artery involvement in children with Kawasaki disease: risk factors from analysis of serial normalized measurements. Circulation 2007; 116: 174-179.

22. Kurotobi S, Nagai T, Kawakami N, Sano T. Coronary diameter in normal infants, children and patients with Kawasaki disease. Pediatr Int 2002; 44: 1-4.

23. Sittiwangkul R, Pongprot Y, Silvilairat S, Phomphutkul C. Delayed diagnosis of Kawasaki disease: risk factors and outcome of treatment. Ann Trop Paediatr 2011; 31: 109-114.

24. Tremoulet AH, Jain S, Chandrasekar D, Sun X, Sato Y, Burns JC. Evolution of laboratory values in patients with Kawasaki disease. Pediatr Infect Dis J 2011; 30: 1022-1026.

25. Yellen ES, Gauvreau K, Takahashi M, et al. Performance of 2004 American Heart Association recommendations for treatment of Kawasaki disease. Pediatrics 2010; 125: e234-e241.

26. Watanabe T, Abe Y, Sato S, Uehara Y, Ikeno K, Abe T. Sterile pyuria in patients with Kawasaki disease originates from both the urethra and the kidney. Pediatr Nephrol 2007; 22: 987-991.

27. Wirojanan J, Sopontammarak S, Vachvanichsanong P. Sterile pyuria in Kawasaki disease. Pediatr Nephrol 2004; 19: 363.

28. Mason WH, Schneider T, Takahashi M. The epidemiology and etiology of Kawasaki disease. Cardiol Young 1991; 1: 196-205.

29. Sepahi MA, Miri R, Ahmadi HT. Association of sterile pyuria and coronary artery aneurysm in Kawasaki syndrome. Acta Med Iran 2011; 49: 606-611.